Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308903512> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4308903512 endingPage "S8" @default.
- W4308903512 startingPage "S8" @default.
- W4308903512 abstract "<h3>Introduction</h3> Vaccination has proven efficacy against COVID-19, yet allergic or adverse reactions have resulted in vaccine hesitancy nationwide. Graded or split dosing of vaccines is a relatively common allergy practice that is understudied for efficacy, particularly for COVID-19. We aimed to compare antibody responsiveness and safety of split versus conventional dosing of COVID-19 vaccines. <h3>Methods</h3> A total of 30 adult subjects received conventional/full (N=15) or 2-step split (N=15) dosing of a COVID-19 vaccine. Pre- and 6-week post-serum antibody levels were determined by multiplex, microsphere-based IgG quantitative assays for SARS-CoV-2 antigens including Receptor Binding Domain (RBD), Spike protein 1 (S1), and nucleocapsid (natural infection marker). The majority received Pfizer booster (73%). Any adverse reactions were recorded. <h3>Results</h3> Post-vaccine RBD and S1 (but not nucleocapsid) antibody expression as measured by mean fluorescent intensity increased in conventional (p=0.0006 and p=0.0054, respectively) and split (p<0.0001 and p=0.0002) dosed subjects. Findings persisted after removal of 3 subjects with evidence of new natural infection as determined by nucleocapsid antibody positive conversion. There was no difference in mean fold-change (post/pre) antibody expression for RBD (conventional: +5.3 vs. split: +26.7, p=0.22) and S1 (+11.7 vs. +27.3, p=0.26). Split dosing was overall well-tolerated with minimal adverse reactions. <h3>Conclusion</h3> Split dosing is safe and non-inferior in efficacy as evidenced by antibody responsiveness when compared to conventional dosing of the COVID-19 vaccines. This approach could be applied to persons with vaccine hesitancy of various reasons including allergic disease(s) to provide immunization against this pandemic and be modeled in future pandemic scenarios." @default.
- W4308903512 created "2022-11-19" @default.
- W4308903512 creator A5017027876 @default.
- W4308903512 creator A5018125963 @default.
- W4308903512 creator A5024554459 @default.
- W4308903512 creator A5026618343 @default.
- W4308903512 creator A5033512204 @default.
- W4308903512 creator A5033730087 @default.
- W4308903512 creator A5072430803 @default.
- W4308903512 creator A5087788769 @default.
- W4308903512 date "2022-11-01" @default.
- W4308903512 modified "2023-09-24" @default.
- W4308903512 title "SPLIT-DOSING OF COVID-19 VACCINES IS SAFE AND PROVIDES NON-INFERIOR ANTIBODY RESPONSIVENESS TO CONVENTIONAL VACCINE DOSING" @default.
- W4308903512 doi "https://doi.org/10.1016/j.anai.2022.08.531" @default.
- W4308903512 hasPublicationYear "2022" @default.
- W4308903512 type Work @default.
- W4308903512 citedByCount "0" @default.
- W4308903512 crossrefType "journal-article" @default.
- W4308903512 hasAuthorship W4308903512A5017027876 @default.
- W4308903512 hasAuthorship W4308903512A5018125963 @default.
- W4308903512 hasAuthorship W4308903512A5024554459 @default.
- W4308903512 hasAuthorship W4308903512A5026618343 @default.
- W4308903512 hasAuthorship W4308903512A5033512204 @default.
- W4308903512 hasAuthorship W4308903512A5033730087 @default.
- W4308903512 hasAuthorship W4308903512A5072430803 @default.
- W4308903512 hasAuthorship W4308903512A5087788769 @default.
- W4308903512 hasBestOaLocation W43089035122 @default.
- W4308903512 hasConcept C126322002 @default.
- W4308903512 hasConcept C147483822 @default.
- W4308903512 hasConcept C159654299 @default.
- W4308903512 hasConcept C197934379 @default.
- W4308903512 hasConcept C203014093 @default.
- W4308903512 hasConcept C22070199 @default.
- W4308903512 hasConcept C2777288759 @default.
- W4308903512 hasConcept C2779134260 @default.
- W4308903512 hasConcept C3008058167 @default.
- W4308903512 hasConcept C524204448 @default.
- W4308903512 hasConcept C71924100 @default.
- W4308903512 hasConceptScore W4308903512C126322002 @default.
- W4308903512 hasConceptScore W4308903512C147483822 @default.
- W4308903512 hasConceptScore W4308903512C159654299 @default.
- W4308903512 hasConceptScore W4308903512C197934379 @default.
- W4308903512 hasConceptScore W4308903512C203014093 @default.
- W4308903512 hasConceptScore W4308903512C22070199 @default.
- W4308903512 hasConceptScore W4308903512C2777288759 @default.
- W4308903512 hasConceptScore W4308903512C2779134260 @default.
- W4308903512 hasConceptScore W4308903512C3008058167 @default.
- W4308903512 hasConceptScore W4308903512C524204448 @default.
- W4308903512 hasConceptScore W4308903512C71924100 @default.
- W4308903512 hasIssue "5" @default.
- W4308903512 hasLocation W43089035121 @default.
- W4308903512 hasLocation W43089035122 @default.
- W4308903512 hasOpenAccess W4308903512 @default.
- W4308903512 hasPrimaryLocation W43089035121 @default.
- W4308903512 hasRelatedWork W1572283981 @default.
- W4308903512 hasRelatedWork W1994361489 @default.
- W4308903512 hasRelatedWork W2040191638 @default.
- W4308903512 hasRelatedWork W206168401 @default.
- W4308903512 hasRelatedWork W2947337648 @default.
- W4308903512 hasRelatedWork W3026647284 @default.
- W4308903512 hasRelatedWork W3115932594 @default.
- W4308903512 hasRelatedWork W3207425030 @default.
- W4308903512 hasRelatedWork W4307171467 @default.
- W4308903512 hasRelatedWork W940191291 @default.
- W4308903512 hasVolume "129" @default.
- W4308903512 isParatext "false" @default.
- W4308903512 isRetracted "false" @default.
- W4308903512 workType "article" @default.